DK2717692T3 - Tetrahydrocannabinol-11-syrer til anvendelse til behandling af fibrotiske sygdomme - Google Patents
Tetrahydrocannabinol-11-syrer til anvendelse til behandling af fibrotiske sygdomme Download PDFInfo
- Publication number
- DK2717692T3 DK2717692T3 DK12796691T DK12796691T DK2717692T3 DK 2717692 T3 DK2717692 T3 DK 2717692T3 DK 12796691 T DK12796691 T DK 12796691T DK 12796691 T DK12796691 T DK 12796691T DK 2717692 T3 DK2717692 T3 DK 2717692T3
- Authority
- DK
- Denmark
- Prior art keywords
- tetrahydrocannabinol
- treatment
- acids used
- fibrotic diseases
- fibrotic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161493435P | 2011-06-04 | 2011-06-04 | |
| US13/485,044 US20120309820A1 (en) | 2011-06-04 | 2012-05-31 | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
| PCT/US2012/040380 WO2012170290A1 (en) | 2011-06-04 | 2012-06-01 | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2717692T3 true DK2717692T3 (da) | 2019-11-11 |
Family
ID=47262154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12796691T DK2717692T3 (da) | 2011-06-04 | 2012-06-01 | Tetrahydrocannabinol-11-syrer til anvendelse til behandling af fibrotiske sygdomme |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20120309820A1 (da) |
| EP (2) | EP2717692B1 (da) |
| DK (1) | DK2717692T3 (da) |
| ES (1) | ES2753639T3 (da) |
| HU (1) | HUE047419T2 (da) |
| PL (1) | PL2717692T3 (da) |
| PT (1) | PT2717692T (da) |
| WO (1) | WO2012170290A1 (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2956133A4 (en) * | 2013-02-12 | 2016-12-21 | Corbus Pharmaceuticals Inc | ULTRAPURIC TETRAHYDROCANNABINOL-11-OIC ACIDS |
| JP6307290B2 (ja) * | 2013-03-06 | 2018-04-04 | 東京応化工業株式会社 | レジスト組成物、レジストパターン形成方法 |
| WO2015200049A1 (en) | 2014-06-26 | 2015-12-30 | Island Breeze Systems Ca, Llc | Mdi related products and methods of use |
| EP3399974A4 (en) * | 2016-01-08 | 2019-09-04 | Colonaryconcepts LLC | FOOD-BASED DELIVERY OF CANNABINOIDS |
| US20190060300A1 (en) * | 2016-03-04 | 2019-02-28 | Sharon Anavi-Goffer | Self-Emulsifying Compositions of CB2 Receptor Modulators |
| CN109715152A (zh) * | 2016-04-29 | 2019-05-03 | 柯巴斯医药有限公司 | 医治感染的方法 |
| US20210284621A1 (en) * | 2018-05-31 | 2021-09-16 | Corbus Pharmaceuticals, Inc. | Cannabinoids and uses thereof |
| US20210267959A1 (en) * | 2018-07-17 | 2021-09-02 | The Regents Of The University Of California | Methods of treating renal disease |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| JP2023520727A (ja) | 2020-04-08 | 2023-05-18 | ミッション セラピューティクス リミティド | Ｕｓｐ３０阻害剤として活性を有するｎ－シアノピロリジン |
| EP4157834A1 (en) | 2020-05-28 | 2023-04-05 | Mission Therapeutics Limited | N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction |
| CN115698001A (zh) | 2020-06-04 | 2023-02-03 | 特殊治疗有限公司 | 具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物 |
| WO2021249909A1 (en) | 2020-06-08 | 2021-12-16 | Mission Therapeutics Limited | 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507767B2 (en) * | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
| AU2003303376A1 (en) * | 2002-12-19 | 2004-07-22 | University Of Massachusetts | Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators |
| US8058227B2 (en) * | 2006-10-03 | 2011-11-15 | Medical University Of South Carolina | Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD |
| US8877188B2 (en) * | 2010-05-04 | 2014-11-04 | The Brigham And Women's Hospital, Inc. | Detection and treatment of non-dermal fibrosis |
-
2012
- 2012-05-31 US US13/485,044 patent/US20120309820A1/en not_active Abandoned
- 2012-06-01 EP EP12796691.9A patent/EP2717692B1/en active Active
- 2012-06-01 PT PT127966919T patent/PT2717692T/pt unknown
- 2012-06-01 DK DK12796691T patent/DK2717692T3/da active
- 2012-06-01 ES ES12796691T patent/ES2753639T3/es active Active
- 2012-06-01 WO PCT/US2012/040380 patent/WO2012170290A1/en unknown
- 2012-06-01 HU HUE12796691A patent/HUE047419T2/hu unknown
- 2012-06-01 EP EP19190296.4A patent/EP3620211A1/en not_active Withdrawn
- 2012-06-01 PL PL12796691T patent/PL2717692T3/pl unknown
-
2016
- 2016-02-29 US US15/057,017 patent/US20160367518A1/en not_active Abandoned
-
2017
- 2017-06-09 US US15/619,089 patent/US20180116999A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2717692B1 (en) | 2019-08-07 |
| EP2717692A4 (en) | 2015-02-18 |
| ES2753639T3 (es) | 2020-04-13 |
| US20120309820A1 (en) | 2012-12-06 |
| WO2012170290A1 (en) | 2012-12-13 |
| US20160367518A1 (en) | 2016-12-22 |
| HUE047419T2 (hu) | 2020-04-28 |
| EP3620211A1 (en) | 2020-03-11 |
| PL2717692T3 (pl) | 2020-06-15 |
| PT2717692T (pt) | 2019-11-18 |
| EP2717692A1 (en) | 2014-04-16 |
| US20180116999A1 (en) | 2018-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTC2785706I2 (lt) | Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui | |
| DK2717692T3 (da) | Tetrahydrocannabinol-11-syrer til anvendelse til behandling af fibrotiske sygdomme | |
| CY2019015I1 (el) | Χρηση πυριτικου ζιρκονιου για τη θεραπεια της υπερκαλιαιμιας | |
| DK2919796T3 (da) | Brug af akkermansia til behandling af stofskiftesygdomme | |
| DK3473278T3 (da) | Fremgangsmåde til enzymatisk behandling af vævsprodukter | |
| DK2707029T3 (da) | Fremgangsmåder til at behandle eller forebygge kolesterolrelaterede sygdomme | |
| CO6960555A2 (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| DK2701733T3 (da) | Forbindelser til behandling af neuropsykiatriske forstyrrelser | |
| DK3520805T3 (da) | Sammensætninger til behandling af myelofibrose | |
| DK2717941T3 (da) | Behandling af cancer | |
| DK3011936T3 (da) | Vævsmanipulerede konstrukter | |
| BR112014013850A2 (pt) | conjunto de prateleiras | |
| BR112014007029A2 (pt) | métodos aperfeiçoados de terapia gênica | |
| DK2627345T3 (da) | Formuleringer til behandling af sygdomme i de øvre luftveje | |
| DK3581199T3 (da) | Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis | |
| BR112013022820A2 (pt) | método de tratamento | |
| DK2554172T3 (da) | Fremgangsmåde til behandling af sygdomme | |
| DK2985275T3 (da) | Fremgangsmåde til oprensning af beta-hydroxy-beta-methylsmørsyre | |
| CO6880064A2 (es) | Métodos terapéuticos | |
| DK2892556T3 (da) | Sammensætninger og fremgangsmåder til behandling af sygdomme | |
| DK2701707T3 (da) | Fremgangsmåde til behandling af dyskinesi | |
| DK2673363T3 (da) | Behandling af angiogenesesygdomme | |
| FI20116093L (fi) | Vettä käsittelevä laitos | |
| DK2694049T3 (da) | Tapentadol til forebyggelse af kronificering af smerte | |
| DK2694056T3 (da) | Terapeutisk behandling |